



## Yposkesi to attend “Bpifrance Inno Génération”

On October 12<sup>th</sup>, 2017 in Paris

**Evry, France, October 6<sup>th</sup>, 2017** - Yposkesi, the first French pharmaceutical company to develop and manufacture gene and cell therapy products for rare diseases, created by AFM-Téléthon and the SPI fund managed by Bpifrance, announced today its participation to the event “Bpifrance Inno Génération” to be held on October 12<sup>th</sup>, 2017 at AccorHotels Arena, in Paris (France).

**Alain Lamproye**, CEO of Yposkesi, will participate in a workshop session entitled “**Gene therapy: the balance between promise, precaution and business**”, moderated by **Prof. Alain Fischer**, on **October 12<sup>th</sup>, 2017 at 11:15am**.

Alain Fischer is a medical doctor, a professor in pediatric immunology and a researcher. He holds since 2011 the position of scientific director of the Imagine Institute and also holds the experimental medicine chair at the College de France. The research work of Prof. Fischer is dedicated to the identification of genetic and molecular basis of hereditary diseases causing immune deficiency and leading to greater susceptibility to infections, allergies, auto-inflammatory diseases and cancers. He is namely renowned for his research work carried out on “bébé-bulles”<sup>1</sup>.

*“We are very pleased to attend this event and honored to participate in the workshop session on gene therapy with Prof. Alain Fischer”, commented Alain Lamproye, CEO of Yposkesi. “Alain Fischer’s work has inspired many researchers to try and develop gene and cell therapies, namely for patients suffering from rare diseases with high unmet medical needs. At Yposkesi, our mission is to take the industrialization process to the next step, which is essential to increase the availability of these treatments for patients”.*

The third edition of the event, which expects around 30,000 attendees, aims at promoting innovation which is today fueled by tomorrow’s entrepreneurs and industry leaders through thematic and interactive workshop sessions, business meetings and innovation demonstrations from all sectors.

**For meeting requests, please send an email to [contact@yposkesi.com](mailto:contact@yposkesi.com).**

### ABOUT YPOSKESI

Yposkesi is a European industrial leader for Gene and Cell Therapy with the mission of developing, manufacturing and making available Gene and Cell therapy treatments to patients affected with rare diseases. It was launched in November 2016 in Evry (France) by the patient organisation AFM-Téléthon with the support of the SPI fund from the French Public Investment Bank (BPI France), with a total investment of €121M. It is made up of 150 experts in bioproduction and has a first production building covering 5’000 m2. The broad expertise of Yposkesi covers the production of viral vectors for gene therapy (Lentivirus & AAV), transduction of hematopoietic stem cells and production of human pluripotent stem cells, with also significant efforts in developing innovative process for large-scale cost-effective manufacturing process of these highly complex ATMPs. The plans are to extend the production capacity with two additional buildings for a total of 13’000 m2 by 2021.

For more information, please visit our website at: [www.yposkesi.com](http://www.yposkesi.com)

---

<sup>1</sup> In March 1999, Alain Fischer, Marina Cavazzana-Calvo, Salima Hacein- Bey-Abina and their teams from Inserm, the AP-HP and Paris Descartes University treated for the first time via gene therapy children suffering from a disease depriving them from their immune defenses.

**PRESS CONTACTS**

**ALIZE RP**

Caroline Carmagnol & Margaux Pronost

**Mail:** [yposkesi@alizerp.com](mailto:yposkesi@alizerp.com)

**Phone:** +33 1 44 54 36 65